LSE - Delayed Quote USD
Editas Medicine, Inc. (0IFK.L)
1.6900
+0.0800
+(4.97%)
At close: May 2 at 7:08:05 PM GMT+1
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 10 | 10 | 14 | 13 |
| Avg. Estimate | 706.1k | 1.21M | 11.66M | 7.01M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 2.5M | 5M | 42M | 25M |
| Year Ago Sales | 1.14M | 513k | 32.31M | 11.66M |
| Sales Growth (year/est) | -37.79% | 135.11% | -63.93% | -39.90% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| 0IFK.L | -- | -- | -- | -- |
| S&P 500 | 12.40% | 3.81% | 8.28% | 13.79% |
Upgrades & Downgrades
| Initiated | HC Wainwright & Co.: Buy | 4/28/2025 |
| Maintains | Evercore ISI Group: Outperform to Outperform | 12/16/2024 |
| Downgrade | JP Morgan: Neutral to Underweight | 12/16/2024 |
| Maintains | RBC Capital: Sector Perform to Sector Perform | 12/13/2024 |
| Maintains | Barclays: Equal-Weight to Equal-Weight | 12/13/2024 |
| Downgrade | Chardan Capital: Buy to Neutral | 12/13/2024 |